key: cord-0849426-7nck0sh2
authors: Syed, Maha N.; Shah, Mohsin; Shin, Daniel B.; Wan, Marilyn T.; Winthrop, Kevin L.; Gelfand, Joel M.
title: Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic
date: 2020-08-26
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.08.095
sha: 6896cdcfb2dc257edda109c9448e6d5cc6c7b0b9
doc_id: 849426
cord_uid: 7nck0sh2

nan

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract 1 infections and related symptoms in psoriasis patients -A meta-estimate of pivotal 2 phase 3 trials relevant to decision-making during the COVID-19 pandemic 

The risk of respiratory tract infections and 95 symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate 96 of pivotal trials relevant to decision-making during the COVID-19 pandemic

The Risk of Respiratory Tract 99 Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-100

Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic

Trials of anti-103 tumour necrosis factor therapy for COVID-19 are urgently needed

Characteristics 105 associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the 106 COVID-19 Global Rheumatology Alliance physician-reported registry

Ongoing Clinical Trials for the Management of the COVID-19